Johnson & Johnson is to form a consortia with leading global research institutions and non-government organisations to work in conjunction with Janssen Pharmaceutical Companies to accelerate the development of its Ebola vaccine.
The Innovative Medicines Initiative (IMI) plans to award these consortia grants totaling more than €100 million from the Ebola+ programme to support the development, manufacturing and patient education for the vaccine regimen. The IMI is Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding for the…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
